XENE: Xenon Pharmaceuticals Inc. Market Capitalization-to-Revenue Ratio

Corporate company logo of Xenon Pharmaceuticals Inc. (XENE)

Innovations in ion channels and the success of the drug Azetukalner are driving the growth of Xenon Pharmaceuticals (XENE). The company's normalized P/S ratio reflects the business valuation relative to revenue, while 710.90 captures a new level. High dependence on a single key product creates biotechnological risks. Ultimately, the company is developing an advanced treatment system for severe neurological pathologies.

Price-to-Revenue Ratio: xenon-pharma.com (XENE) for 07/04/2022 - 05/08/2026

Analytical breakdowns for Xenon Corp (XENE)

- share price and expert price forecast:
- market capitalization information:
General company analysis:XENE (Xenon)
Original product of Xenon Pharmaceuticals Inc

The P/S ratio evaluates the market value of Xenon Pharmaceuticals (XENE) relative to its annual revenue, allowing investors to determine the premium paid per unit of sales. By analyzing the history of P/S values, where the current level is 710.90, one can correlate capitalization with the efficiency of substance logistics for neuro-research, the continuity and strict adherence to delivery protocols of which form the fundamental basis of the company's cash flow.

Competing companies

BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|VKTX: P/S Multiple|Price-to-Sales Ratio SUPN (Supernus)|CPRX (Catalyst Pharmaceuticals Inc) - P/S Multiple|DNLI: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio harmonybiosciences.com (HRMY)|Biohaven - Market Cap to Revenue Ratio|P/S Multiple AMLX (amylyx.com)|Trevi Pharma (TRVI) - Price to Sales|Praxis Corp - P/S Multiple|Anavex Corp (AVXL) - Market Cap to Revenue|CBLL: P/S Multiple|Prothena Biosciences - Market Capitalization-to-Revenue Ratio|ALEC (alector.com) - P/S Multiple|Market Cap to Revenue Ratio ANNX (Annexon Biosciences)|Price-to-Revenue Ratio Omeros Corporation (OMER)|Neurogene Corp - Market Cap to Revenue Ratio|Price-to-Revenue Ratio AC Immune S.A. ACIU|Price-to-Revenue Coefficient Voyager Therapeutics (VYGR)|Neumora - P/S Multiple|Price-to-Sales Ratio SCLX|Tevogen Bio Inc. (TVGN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio ACOG|CGTX (cogrx.com) - P/S Multiple|Market Cap to Revenue inhibikase.com (IKT)|Price-to-Revenue Ratio Cassava Sciences Inc (SAVA)|Price-to-Revenue Coefficient Assertio|P/S Multiple COYA (Coya Therapeutics, Inc.)|Market Cap to Sales Volume VTGN (VistaGen Therapeutics Inc)|OVID: Market Cap to Revenue|ABOS: Price-to-Revenue Ratio|CervoMed (CRVO) - Price-to-Revenue Ratio|Price to Sales Alterity Therapeutics Ltd (ATHE)|CLNN (Clene) - P/S Multiple|Market Cap to Revenue Ratio PEPG (PepGen)|Market Cap to Revenue JUNS (Jupiter Neurosciences, Inc.)|P/S Multiple relmada.com (RLMD)|Price-to-Revenue Ratio Annovis Bio Corp ANVS|GRCE: Market Cap to Revenue Ratio|AIFF - Price-to-Revenue Ratio|KLTO (anewmeds.com) - Market Cap to Revenue Ratio|NRSN (NeuroSense Therapeutics Ltd.) - Market Cap to Revenue|revivapharma.com - Market Capitalization-to-Revenue Ratio|MTVA (metaviatx.com) - P/S Multiple|NRXS: Market Capitalization-to-Revenue Ratio|P/S Multiple HSDT|PASG - Price to Sales|P/S Multiple NEUP (Neuphoria Therapeutics)|NERV: Market Cap to Revenue Ratio|ATHA: Market Cap to Revenue|Addex Therapeutics Ltd - Market Cap to Sales Volume|Alzamend Neuro, Inc. (ALZN) - Price-to-Revenue Ratio|CYCN (Cyclerion Therapeutics Inc.) - Price-to-Revenue Ratio|Market Cap to Revenue PTIX|KTTA: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Brainstorm Cell Therapeutics, Inc. BCLI|Market Capitalization-to-Revenue Ratio CARA|chromocell.com - P/S Multiple|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|Price to Sales Longboard Pharmaceuticals, Inc. (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue